Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017099591) TREATMENT OF INHIBITOR RESISTANT BRAF-MUTANT CANCERS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/099591 International Application No.: PCT/NL2016/050851
Publication Date: 15.06.2017 International Filing Date: 06.12.2016
IPC:
A61K 31/7068 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7042
Compounds having saccharide radicals and heterocyclic rings
7052
having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706
containing six-membered rings with nitrogen as a ring hetero atom
7064
containing condensed or non-condensed pyrimidines
7068
having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS [NL/NL]; 121, Plesmanlaan 1066 CX Amsterdam, NL
Inventors:
POELL, Jos Bernard; NL
BEIJERSBERGEN, Rodrigo Leonardus; NL
Agent:
ALGEMEEN OCTROOI- EN MERKENBUREAU B.V.; NL
Priority Data:
201591607.12.2015NL
Title (EN) TREATMENT OF INHIBITOR RESISTANT BRAF-MUTANT CANCERS
(FR) TRAITEMENT DE CANCERS À MUTATION BRAF RÉSISTANTS AUX INHIBITEURS
Abstract:
(EN) The disclosure relates to improved methods of treatment of cancer, in particular cancer that is resistant to treatment with MAPK pathway inhibitors, for example has acquired resistance to such MAPK pathway inhibitors. The disclosure provides pharmaceutical compositions for use in such treatment, treatment schedules using such compositions and method of treatment. The invention is based on the use of PKC activators.
(FR) L'invention concerne des méthodes de traitement du cancer, notamment du cancer qui est résistant à un traitement par des inhibiteurs de la voie MAPK, par exemple ayant acquis une résistance aux dits inhibiteurs de la voie MAPK. La présente invention concerne des compositions pharmaceutiques destinées à être utilisées dans un tel traitement, des programmes thérapeutiques utilisant de telles compositions et un procédé de traitement. L'invention est basée sur l'utilisation d'activateurs de PKC.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)